A few days ago, it was announced that India’s first vaccine against Coronavirus, Covaxin, developed by Bharat Biotech India Limited, in association with ICMR and National Institute of Virology, was given approval for human trials by the DGCA.
Several centers all over India have been selected for the testing of the virus on humans. According to the latest reports, more than 1,000 people will be tested here in Hyderabad itself, as part of phase 1 and 2 of testing.
The vaccine has been developed from a deactivated sample of the virus itself, which was extracted from an asymptomatic patient earlier this year. The sample was then weakened so that it wouldn’t react or multiply when injected into a person’s body.
This weakened form of the virus will boost the infected person’s immunity, thereby enabling the patient to fight against the virus.
If everything goes well, the vaccine might be available for public use by August 15th.